Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

AbbVie (ABBV) and Catalyst Pharmaceuticals (CPRX): Analyzing Investment Potential

The pharmaceutical industry’s inelastic demand for its products helps it to weather economic downturns. With fears of an impending recession playing on the minds of investors, it could be wise to buy fundamentally strong pharmaceutical stock AbbVie (ABBV). On the other hand, given its mixed fundamentals and profitability, it could…

StockNews.com

A landmark appeals court ruling clears way for Purdue Pharma-Sackler bankruptcy deal

The 2nd Circuit Court of Appeals in New York cleared the way for a controversial bankruptcy deal that grants immunity from opioid lawsuits to members of the Sackler family.

WEKU

‘I yelled, “I’m putting this up your nose”’: what it’s like to use Narcan

Four people on using the nostril-based antidote to opioid overdoses, newly approved for over-the-counter sale

The Guardian - US

From analysis to the latest developments in health,
read the most diverse news in one place.

CVS Health (CVS) vs. MedAvail Holdings (MDVL): Which Is the Better Buy?

The drug store industry is well positioned for long-term growth thanks to the growing demand for prescription drugs. Let’s compare CVS Health (CVS) and MedAvail (MDVL) in this space to determine which is better positioned to capitalize on the industry’s solid growth prospects….

StockNews.com

The Nottinghamshire pharmacies which failed to meet all standards during inspections

"Whilst the national report looked pretty daunting I’ve not found anything for significant cause for concern"

Nottingham Post

UK response to Covid pandemic was 'fuelled by nationalism'

THE UK’S response to the Covid pandemic has been branded “colonial” and “fuelled by nationalism” by justice campaigners.

The National (Scotland)

Oregon, awash in treatment funds after decriminalizing drugs, now must follow the money

Funding for drug treatment centers in Oregon, financed by the state’s pioneering drug decriminalization policy, stands these days at over a quarter-billion dollars

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

US drug firm loses license after ignoring suspiciously large painkiller orders during opioid crisis

Morris & Dickson Co.'s license has been revoked by the US Drug Enforcement Administration (DEA) following a 68-page order by DEA Administrator Anne Milgram on the opioid crisis

Daily Mirror

DEA moves to revoke major drug distributor's license over opioid crisis failures

The agency says it will strip Morris & Dickson of its license to sell highly addictive painkillers after finding it failed to flag thousands of suspicious orders at the height of the opioid crisis.

WEKU

After yearslong delay, DEA revokes license of wholesale drug distributor over opioid crisis failures

The U.S. Drug Enforcement Administration has stripped one of the nation’s largest pharmaceutical distributors of its license to sell highly addictive painkillers after determining it failed to flag thousands of suspicious, high-volume orders at the height of the opioid crisis

The Independent UK

US banker paid £73m dividend in 2021 after firm won millions in UK Covid contracts

Banks Bourne, sole owner of Tanner Pharma in North Carolina, took sum from Tanner’s UK arm, records show

The Guardian - UK

Analysts expect Medtronic to deliver frank financial answers this week

Medtronic is facing sluggish sales growth, is in the midst of deep cost-cutting and started ongoing global layoffs in April. It's also spinning off businesses with weaker profit margins.

Tribune News Service

3 Biotech Stocks Losing Market Value

There is a growing demand for healthcare solutions, and the biotech industry will likely benefit from it. However, not all biotech stocks are well-positioned to capitalize on the industry tailwinds. Therefore, investors could look to avoid fundamentally weak biotech stocks Bicycle Therapeutics (BCYC), CorMedix (CRMD), and 22nd Century Group (XXII).…

StockNews.com

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

Salon

GOP moves to limit abortion pill in US

A House panel advanced a 2024 budget bill that would block the ability to access the abortion drug via telehealth

The Independent UK

Takeaways of AP report on DEA probe of drug distributor accused of fueling opioid epidemic

The U.S. Drug Enforcement Administration has allowed one of the nation’s largest drug distributors to keep shipping addictive painkillers for nearly four years despite a judge’s recommendation to strip its license for turning a blind eye to thousands of suspicious opioid orders

StockNews.com

Invest in These 3 Biotech Stocks Today

With the biotech industry experiencing significant growth due to the increasing demand for healthcare solutions, fundamentally sound stocks such as Amicus Therapeutics (FOLD), POINT Biopharma Global (PNT), and Precision BioSciences (DTIL) might have the potential to provide substantial returns for investors and could be valuable portfolio additions this month. Learn…

StockNews.com

Johnson & Johnson (JNJ) and SNDL Inc. (SNDL) -- Buy or Sell?

Investing in healthcare stocks could help hedge against economic downturns. Thus, Johnson & Johnson (JNJ) could be worth buying. However, I think SNDL (SNDL) is best avoided considering its weak fundamentals. Read on.

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

Explained | What is the National Medical Devices Policy, 2023?

On April 26, the Union Cabinet approved the National Medical Devices Policy, 2023.Here are the various reasons why it is imporetant

The Guardian - UK

HRT medicine Utrogestan restricted in UK amid shortages

Pharmacists can only dispense maximum of two months’ supply for every prescription as supplier struggles to meet demand

StockNews.com

2 Explosive Biotech Stocks to Own

The biotech industry is well-positioned to grow, thanks to breakthrough advances, rising chronic illness and government support. So, fundamentally solid biotech stocks, Genmab (GMAB) and Exelixis (EXEL) may be worth buying now. Read on.

StockNews.com

Dr. Reddy's Laboratories (RDY) Is the Pharmaceutical Stock to Buy

Dr. Reddy's Laboratories (RDY) delivered exceptional performance, as its fourth-quarter profits grew by an astonishing eleven-fold. By deftly expanding its product line-up and fortifying its market presence, the company sets the stage for significant growth, which could establish it as the go-to pharmaceutical stock to invest in. Read more….

Bangkok Post

AstraZeneca China boss pledges to ‘love the Communist Party’

BEIJING: The global drugmaker AstraZeneca will seek to be a patriotic company in China that “loves the Communist Party”, its China president said on Friday.

StockNews.com

2 Pharma Stocks Investors Are Flocking

The pharmaceutical industry is expected to thrive amid robust demand and government support. Given the solid long-term prospects of the industry, investors should consider buying pharma stocks Ironwood Pharmaceuticals (IRWD) and Calliditas Therapeutics (CALT). Read on.

StockNews.com

2 Pharma Stocks to Watch Like a Hawk

From innovative drug pipelines to innovative research, the pharma sector offers a vast array of investment opportunities. Thus it would be wise to keep an eye on quality stocks Ipsen S.A.(IPSEY) and Kamada (KMDA), which hold considerable potential. Read more….

1 … 53 54 55 56

People

Joe Biden

68,729 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

The Federal Trade Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.